Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):572–576. doi: 10.1038/bjc.1994.104

Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.

G Cortesina 1, A De Stefani 1, E Galeazzi 1, G P Cavallo 1, F Badellino 1, G Margarino 1, C Jemma 1, G Forni 1
PMCID: PMC1968846  PMID: 8123489

Abstract

The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One complete response (CR) and three partial responses (PRs) were observed in the 16 patients who received 500 U of IL-2, whereas the higher dose was not effective. The CR was recorded in one of the seven patients with a oropharyngeal recurrence. Partial responses were obtained in 1/5 patients with hypopharyngeal recurrences, in 1/5 patients with oral cavity recurrences and 1/7 patients with laryngeal recurrences. The duration of the responses was 3-5 months and additional courses of ten injections of IL-2 had no further effect.

Full text

PDF
572

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bocci V. Immunomodulators as local hormones: new insights regarding their clinical utilization. J Biol Response Mod. 1985 Aug;4(4):340–352. [PubMed] [Google Scholar]
  2. Bosco M., Giovarelli M., Forni M., Modesti A., Scarpa S., Masuelli L., Forni G. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol. 1990 Nov 1;145(9):3136–3143. [PubMed] [Google Scholar]
  3. Colombo M. P., Modesti A., Parmiani G., Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 1992 Sep 15;52(18):4853–4857. [PubMed] [Google Scholar]
  4. Cortesina G., Cavallo G. P., Beatrice F., Sartoris A., Bussi M., Morra B., Di Fortunato V., Poggio E., Rendine S. Production of leukocyte migration inhibition factor by lymphocytes of larynx cancer patients stimulated by laryngeal carcinoma solubilized membrane antigens. Tumori. 1982 Feb 28;68(1):39–46. doi: 10.1177/030089168206800107. [DOI] [PubMed] [Google Scholar]
  5. Cortesina G., De Stefani A., Galeazzi E., Cavallo G. P., Jemma C., Giovarelli M., Vai S., Forni G. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck. 1991 Mar-Apr;13(2):125–131. doi: 10.1002/hed.2880130208. [DOI] [PubMed] [Google Scholar]
  6. Cortesina G., De Stefani A., Giovarelli M., Barioglio M. G., Cavallo G. P., Jemma C., Forni G. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer. 1988 Dec 15;62(12):2482–2485. doi: 10.1002/1097-0142(19881215)62:12<2482::aid-cncr2820621205>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  7. Forni G., Giovarelli M., Santoni A. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol. 1985 Feb;134(2):1305–1311. [PubMed] [Google Scholar]
  8. Forni G., Giovarelli M., Santoni A., Modesti A., Forni M. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol. 1987 Jun 1;138(11):4033–4041. [PubMed] [Google Scholar]
  9. Gore M. E., Riches P., MacLennan K., O'Brien M., Moore J., Dadian G., Lorentzos A., Garth R., Moskovic E., Archer D. Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck. Br J Cancer. 1992 Aug;66(2):405–407. doi: 10.1038/bjc.1992.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lundy J., Wanebo H., Pinsky C., Strong E., Oettgen H. Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck. Am J Surg. 1974 Oct;128(4):530–533. doi: 10.1016/0002-9610(74)90268-2. [DOI] [PubMed] [Google Scholar]
  11. Morra B., Beatrice F., Cavallo G. P., Bussi M., Di Fortunato V., Poggio E., Vercellino M., Vercellino M., Cortesina G. Evaluation of blocking mechanisms against immunological responses in patients with laryngeal carcinoma. Laryngoscope. 1984 Jun;94(6):825–828. doi: 10.1288/00005537-198406000-00019. [DOI] [PubMed] [Google Scholar]
  12. Rivoltini L., Gambacorti-Passerini C., Squadrelli-Saraceno M., Grosso M. I., Cantù G., Molinari R., Orazi A., Parmiani G. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 1990 Sep 1;50(17):5551–5557. [PubMed] [Google Scholar]
  13. Wolf G. T., Hudson J. L., Peterson K. A., Miller H. L., McClatchey K. D. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986 Sep;95(2):142–152. doi: 10.1177/019459988609500203. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES